Eaton Vance Management’s Editas Medicine EDIT Stock Holding History

Eaton Vance Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,600	Closed	-$43K	–	2046
2021 Q4	$43K	Sell	1,600 -75	-4%	-$2.58K	﹤0.01%	2163
2021 Q3	$25K	Hold	1,675	–	–	﹤0.01%	1611
2021 Q2	$95K	Buy	1,675 +388	+30%	+$14.3K	﹤0.01%	1915
2021 Q1	$54K	Buy	+1,287	New	+$73.3K	﹤0.01%	1775

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Eaton Vance Management's EDIT Position: Q1 2022 in Review

Eaton Vance Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 1,600 shares — an estimated $43K sold.

Eaton Vance Management first reported a position in EDIT in Q1 2021 and held it in 4 quarters. The position peaked at $95K in Q2 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Eaton Vance Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 1,600 Editas Medicine shares in Q1 2022, an estimated $43K.
Eaton Vance Management first reported a position in Editas Medicine in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's Editas Medicine position peaked at $95K in Q2 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.